Federal appeals courts have generally held that the Medical Device Amendments to the Federal Food, Drug and Cosmetic Act pre-empt tort claims relating to medical devices that have undergone the Food and Drug Administration’s rigorous pre-market approval process, when the tort claim would impose requirements that conflict or interfere with the requirements embodied in the FDA’s approval of the device.
But a recent ruling by a federal district court raises the possibility that a medical device manufacturer could lose the benefit of federal pre-emption if a fact-finder determines that the manufacturer failed to disclose a known danger in an approved device. The ruling raises challenging issues regarding the interplay of federal and state law.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
